A Tale of Two Drugs: How the Inflation Reduction Act of 2022 Impacts Drug Classes Differently


Briggs S1, Francois C2, Auger E1, Busch A1
1Putnam, Boston, MA, USA, 2Aix-Marseille University, Marseille, France

OBJECTIVES: The Inflation Reduction Act (IRA) will have several downstream impacts on the cost of healthcare for the U.S. population. This study aimed to assess the potential evolution of the uptake and net sales of different drug classes in the next decade following passage of the IRA.

METHODS: To illustrate how the IRA may impact drug classes differently in the coming years, we selected Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) and Imbruvica (Ibrutinib), a kinase inhibitor indicated for several blood cancers. We evaluated the impact of Medicare Part D benefit redesign, selection by HHS for Medicare price negotiation, increased Medicare rebates, and eligibility for or exemption from subsequent price re-negotiation triggered by “long monopoly” status (16+ years since approval) to estimate the impact on annualized Medicare Net Sales for each product through 2030 vs. a 2022 baseline.

RESULTS: Net sales trends diverge between the 2 products, with Shingrix Medicare net sales peaking at225% of 2022 levels by 2028, driven by elimination of copays for Part D vaccines leading to reduced abandonment rates or increased adherence rates, followed by a subsequent decrease to 167% in 2030. For Imbruvica, increased Medicare rebates and the introduction of a negotiated Maximum Fair Price in 2026 reduce Medicare net sales to 60% of 2022 levels by 2029 and 37% by 2030 following price re-negotiation.

CONCLUSIONS: The analysis illustrates how the IRA will have disparate impact on drugs depending on various factors including drug class, current adherence rates, and net price per patient, leading to either increased or decreased Medicare net sales. This impact is not limited to currently marketed drugs but may extend to novel drug development with industry possibly shifting away from development of the most at-risk drug classes in favor of classes with additional protections.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)




Health Policy & Regulatory

Topic Subcategory

Insurance Systems & National Health Care, Pricing Policy & Schemes, Public Spending & National Health Expenditures, Reimbursement & Access Policy


No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now